Shares of AbbVie (NYSE:ABBV) hit a session low on Tuesday after UnitedHealth (NYSE:UNH) subsidiary Optum announced plans to remove its blockbuster therapy Humira from some of its formulary lists for ...

Spherix Global Insights has provided a different angle on AbbVie’s successful retention of Humira sales in the face of biosimilar competition, polling doctors about forces shaping the market and their ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

High- and low-concentration interchangeable biosimilar will be available, estimated to save individual patients around $3,500 on average per year Biosimilar price will be about 85% lower than Humira ® ...

A top California health plan is set to offer one of the world’s biggest-selling drugs for free in a bid to show the medicine can reach Americans affordably without going through the middlemen that ...

UnitedHealth Group Inc. (NYSE:UNH) reportedly announced on Tuesday that it will remove AbbVie Inc.’s (NYSE:ABBV) blockbuster drug Humira from some of its preferred reimbursement lists starting January ...

Evio Pharmacy Solutions, the for-profit pharmacy solutions company formed by five Blue Cross & Blue Shield licensees, said today it has entered a unique direct-purchase deal for a cheaper version of ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Beginning in 2023, five years after their European counterparts, ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Blue Shield of California is bypassing traditional pharmacy ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...

Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...